FRANKLIN, Tenn., Dec. 13, 2022 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to improving health equity for seniors, today issued December Investor Frequently Asked Questions on its investor relations website at https://investors.cloverhealth.com/investor-resources/FAQs. Clover may provide updates to Investor Frequently Asked questions on its investor website.
Our responses may contain forward-looking statements as defined by Section 27A of Securities Act of 1933, as modified, and Section 21E of Securities Exchange Act of 1934. Forward-looking statements include statements regarding future events and Clover Health’s future plans. Forward-looking statements do not guarantee future performance and should not be relied upon. Additional information concerning these and other risk factors is contained in Clover Health’s latest Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2022, including the Risk Factors section therein, and in its other filings with the SEC. Forward-looking statements in this release reflect the current date. Clover Health is not required to make any forward-looking statements other than as required by law.
Clover Health (Nasdaq : CLOV), a physician-enablement company, is focused on seniors who previously had limited access to high-quality, affordable healthcare. Clover Assistant is our proprietary software platform. This software is designed to collect patient data from all parts of the health ecosystem and help with clinical decision-making. Two distinct business lines are operated by us: Insurance and Non Insurance. We offer HMO and PPO plans to Medicare Advantage members in many states through our Insurance business. Our Non-Insurance division aims at reducing costs and improving the quality of healthcare for Medicare beneficiaries who have enrolled in fee-for service Medicare. Clover’s corporate headquarters are in Franklin, Tenn.
Contact the Press:
Contact us for Investor Relations